Investigators from Federal University of Rio Grande do Sul Target Drug Delivery Systems (The use of chitosan as cationic coating or gel vehicle for polymeric nanocapsules: Increasing penetration and adhesion of imiquimod in vaginal tissue)
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Drugs and Therapies - Drug Delivery Systems. According to news originating from Porto Alegre, Brazil, by NewsRx correspondents, research stated, "The human papillomavirus (HPV) infection, which is strongly related to cervical cancer, can be reduced by the topical application of imiquimod. Some strategies have been used to increase the adhesion and penetration of drugs through the vaginal mucosa."
Financial supporters for this research include Brazilian agencies: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, INCT-Nanofarma/CNPq, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul, PRONEX-FAPERGS/CNPq (see also Drugs and Therapies - Drug Delivery Systems).
Our news journalists obtained a quote from the research from the Federal University of Rio Grande do Sul, "Two of them are the development of mucoadhesive semisolid formulations and the development of polymeric nanocarriers. In this paper, we hypothesize that the combined use of these two strategies results in a better performance of the formulation to retain imiquimod into the vaginal tissue. Aiming this, two different systems are proposed: (a) chitosan-coated poly(e-caprolactone)-nanocapsules incorporated into hydroxyethylcellulose gel (HEC-NCimig-chit), and (b) poly(e-caprolactone)-nanocapsules incorporated into chitosan hydrogel (CHIT-NCimiq). These formulations were submitted to three main tests: mucoadhesivity by interaction, permeation and washability test (or retention test). We developed an integrative index that allows comparing the global performance of the proposed formulations by considering jointly the results of these three tests."
According to the news editors, the research concluded: "Thus, when considered the integrative indexes for the formulations, our results show that CHIT-NCimiq presents the best performance for the treatment of HPV."
For more information on this research see: The use of chitosan as cationic coating or gel vehicle for polymeric nanocapsules: Increasing penetration and adhesion of imiquimod in vaginal tissue. European Journal of Pharmaceutics and Biopharmaceutics, 2017;114():202-212. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.journals.elsevier.com/european-journal-of-pharmaceutics-and-biopharmaceutics/)
The news correspondents report that additional information may be obtained from L.A. Frank, Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Porto Alegre, RS, Brazil. Additional authors for this research include P.S. Chaves, C.M. D'Amore, R.V. Contri, A.G. Frank, R.C.R. Beck, A.R. Pohlmann, A. Button and S.S. Guterres.
Keywords for this news article include: Porto Alegre, Brazil, South America, Topical Antiinfectives, Dermatological Agents, Emerging Technologies, Drug Delivery Systems, Drugs and Therapies, Antiretrovirals, Nanotechnology, Nanocapsules, Imiquimod, Federal University of Rio Grande do Sul.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC